Meeting
2022 ASCO Annual Meeting
Safety, pharmacodynamic, and clinical response evaluation of nilotinib and paclitaxel in adults with refractory solid tumors.
Authors
Sarah Shin
Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
Sarah Shin , Geraldine Helen O'Sullivan Coyne , Shivaani Kummar , Murielle Hogu , Larry V. Rubinstein , Sarah Miller , Naoko Takebe , Lamin Juwara , Larry Anderson , Jerry M. Collins , Richard Piekarz , Elad Sharon , Jiuping Jay Ji , Brandon Miller , Deborah Wilsker , Apurva K. Srivastava , Katherine V. Ferry-Galow , Ralph E. Parchment , James H. Doroshow , Alice P. Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT02379416
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3026)
DOI
10.1200/JCO.2022.40.16_suppl.3026
Abstract #
3026
Poster Bd #
18
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit.
First Author: S. P. Anthony
Poster
2020 ASCO Virtual Scientific Program
Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors.
First Author: Jaime R. Merchan
Poster
2019 ASCO Annual Meeting
A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors.
First Author: Emiliano Calvo
Poster
2019 ASCO Annual Meeting
Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors.
First Author: Arjun Mittra